sponsored
PatientsVille.com Logo

PatientsVille

Upper Respiratory Tract Inflammation Medical Research Studies

Up-to-date List of Upper Respiratory Tract Inflammation Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Upper Respiratory Tract Inflammation Medical Research Studies

Rank Status Study
1 Recruiting Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
Conditions: Allergic Rhinitis;   Asthma;   Latent Tuberculosis
Interventions: Other: TLR Agonist;   Other: Tuberculin nasal challenge;   Other: Timothy Grass Pollen
Outcome Measures: To document a dose response and time course to nasal challenge in terms of cytokine levels in nasal mucosal lining fluid.;   Change in peak nasal inspiratory flow and nasal symptom scores before and after nasal challenge agent.;   To monitor levels of prostaglandin D2 after nasal challenge agent utilising a special probe that touches the surface of the nasal lining and is linked to a mass spectrometer.;   To document a time course and dose response of nasal curettage mRNA expression in response to nasal challenge agents.;   Change in nasal mucosal lining appearance on clinical examination before and after administration of nasal challenge agent.;   Change in blood pressure, pulse, temperature before and after administration of nasal challenge agent.
2 Recruiting Airway Inflammation in Children With Allergic Rhinitis and Intervention
Conditions: Allergic Rhinitis;   Inflammation;   Respiratory Tract Diseases;   Hypersensitivity
Interventions: Drug: Budesonide nasal spray;   Drug: Placebo
Outcome Measures: Change from baseline fractional exhaled nitric oxide (FeNO) at 3 months;   Change from baseline eosinophils in sputum at 3 months;   Changes of lower airway resistance (Z5,R5,X5,R5-20,R20 and Fres) using impulse oscillation;   Change of upper airway inflammation biomarker such as eosinophils in nasal lavage;   Change of cumulative dosage of methacholine causing a 20% fall in forced expiratory volume in 1 second (PD20FEV1-MCH);   To measure the differences in nasal symptoms score (TSS) about groups after 12 weeks of therapy;   The change in visual analogue scale score for symptoms of rhinitis;   Juniper mini RQLQ;   Change in levels of eosinophil(ECP),eosinophil peroxidase(EPO), myeloperoxidase (MPO)and eosinophil-derived neurotoxin (EDN) in induced sputum and serum about groups after twelve weeks of therapy;   Change in forced vital capacity (FVC) , in forced expiratory volume in 1 second (FEV1),in forced expired flow at 25% of FVC(FEF25) and in forced expired flow at 75% of FVC (FEF75) about groups after twelve weeks of therapy.;   Evaluation of the possible association between upper airway inflammation (eosinophil count in nasal lavage) and bronchial (PD20FEV1-MCH,FeNO and eosinophil count in induced sputum).
3 Recruiting Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
Conditions: Pneumonia;   Meningitis;   Bacteraemia;   Sepsis;   Otitis Media
Intervention: Biological: Prevenar 13 and Synflorix
Outcome Measures: Proportion of children with serotype-specific IgG concentration >= 0.35ug/ml at 4 and 9 months of age for 90% of PCV vaccine serotypes and proportion of children with OPA >=1:8 titres at 4, 10 and 24 months;   Compare antibody concentrations to pneumococcal and Haemophilus influenzae protein antigens.;   Determine carriage rates and bacterial load of pneumococci and H.influenzae;   Determine rates of hospital admission for acute respiratory tract infections at 9 and 23 months
4 Not yet recruiting Electronic Algorithms Based on Host Biomarkers Point of Care Tests to Decide on Admission and Antibiotic Prescription in Tanzanian Febrile Children
Condition: Acute Febrile Illness
Interventions: Other: Management of febrile children using e-POCT;   Other: Management of febrile children using ALMANACH
Outcome Measures: Proportion of clinical failure by day 7 compared among the 3 study arms.;   Proportions of secondary hospitalization and death by day 30 compared among the 3 study arms.;   Proportions of children prescribed an antibiotic and/or antimalarial treatment at day 0 and by day 7 compared among the 3 study arms.;   Proportions of children with hypoxemia, stratified by diagnostic classification (e-POCT arm);   Proportion of primarily admitted children compared among the 3 study arms.
5 Unknown  Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Conditions: Inflammation;   Cough;   Rhinitis
Interventions: Drug: diphenhydramine + dropropizine + pseudoephedrine;   Drug: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
Outcome Measures: Improvement of nasal congestion and cough;   Improvement of non-obstructive nasal symptoms;   Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child;   Reduction of vomiting frequency episodes triggered by coughing;   Improvement of acute rhinitis signs;   Use of rescue medication;   Overall impression of improvement by the investigator;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
6 Recruiting Effects of Whole Sprouts on Upper Airway Allergic Inflammation
Conditions: Allergic Rhinitis;   Asthma;   Allergy
Interventions: Drug: Broccoli Sprouts;   Drug: Placebo
Outcome Measures: IL6 levels;   biomarkers of inflammation in nasal epithelial cells;   Respiratory Symptoms;   nasal lavage;   biomarkers of inflammation in blood;   biomarkers of inflammation in urine;   biomarkers of oxidative stress
7 Unknown  Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
Conditions: Nasal Congestion and Inflammations;   Rhinitis
Interventions: Drug: brompheniramine + phenylephrine;   Drug: Brompheniramine + pseudoephedrine
Outcome Measures: Improvement of nasal congestion and runny nose, after 48 hours of treatment;   Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching);   Clinical score of upper airway compromise;   Proportion of subjects who used at least once the rescue medication;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
8 Unknown  Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
Conditions: Nasal Congestion and Inflammations;   Rhinitis
Interventions: Drug: Group 1;   Drug: Group 2
Outcome Measures: Improvement of nasal congestion and runny nose, after 48 hours of treatment;   Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching);   Clinical score of upper airway compromise;   Proportion of subjects who used at least once the rescue medication;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
9 Recruiting Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study
Conditions: Sleep Disordered Breathing;   Obstructive Sleep Apnea;   Adenotonsillectomy;   Snoring;   Obstructive Sleep Disordered Breathing
Intervention: Procedure: Adenotonsillectomy (AT)
Outcome Measures: Change in proportion of subjects without oxygenation abnormalities;   Proportion of subjects with oxygenation abnormalities at baseline who improved at follow-up;   Somatic growth;   Abnormalities predisposing to obstructive sleep apnea (OSA) and OSA symptoms;   Sleepiness;   Behavioral abnormalities-1;   Behavioral abnormalities-2;   Enuresis;   Quality of life;   Cardiovascular effects-1;   Cardiovascular effects-2;   Systemic inflammation;   Effects on sympathetic nervous system activation;   Improvement in baseline SpO2
10 Recruiting Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
Conditions: Chronic Inflammation of Hypopharynx;   Hoarseness;   Macroscopic Laryngeal Lesions;   Histological Confirmation of Dysplasia;   Carcinoma in Situ;   Invasive Carcinoma of Larynx;   Invasive Carcinoma of Hypo Pharynx;   Recurrent Respiratory Papillomatosis
Intervention: Device: NBI endoscopy
Outcome Measures: The number of patients with larger extent of the laryngeal lesison on NBI examination when compared to standard white light endoscopy;   The number of patients with histologically proven laryngeal cancer
11 Recruiting LipoAerosol© Inhalation After Tracheostomy
Condition: Other Tracheostomy Complication
Interventions: Device: LipoAerosol© inhalation;   Other: Physiologic saline inhalation
Outcome Measures: Changes in tracheal interleukin 6 levels;   Changes in the number of suction maneuver, tracheo-bronchial redness, and mucous congestion
12 Recruiting Effect of Different Electric Muscle Stimulation in Patients With Severe Sepsis and Respiratory Failure
Conditions: Severe Sepsis;   Acute Respiratory Failure;   Muscle Hypotonia;   Inflammation;   Weakness
Intervention: Device: EMS
Outcome Measures: ventilator-dependant days;   Muscle strength improvement
13 Unknown  Omalizumab in Non-atopic Asthma
Condition: Bronchial Asthma
Interventions: Drug: Omalizumab;   Drug: Placebo
Outcome Measures: Pre-bronchodilator FEV1;   Disease exacerbation;   Day and night time symptom scores;   Morning and evening peakflows;   Exhaled nitric oxide;   Total dosage of rescue beta-2-agonists;   Total symptom free days;   Quality of life scores;   Markers of airway remodelling and inflammation;   Local IgE synthesis in the bronchial mucosa and its expression
14 Unknown  Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis
Conditions: Nasal Congestion;   Cough
Interventions: Drug: Group 1;   Drug: Group 2
Outcome Measures: Primary efficacy criteria;   Secondary efficacy criteria
15 Unknown  Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype
Conditions: Obstructive Chronic Pulmonary Disease;   Emphysema;   Chronic Bronchitis
Intervention: Other: Combined Training (endurance and strength exercises)
Outcome Measures: Change from baseline in TNF-alpha and its receptors, muscle isoforms of IGF-1 and its receptor in samples of quadriceps muscle satellite cells at 3 moths.;   Pax7, M-cadherin and Myo-D and its receptor in samples (molecules and repair-myogenesis) of quadriceps muscle satellite cells.;   MIC-A and MIC-B soluble in serum.;   CRP, IL6, IL8, IL10, IL12, TNF alpha, IGF-1 (systemic inflammatory profile) in serum.
16 Not yet recruiting Airway Inflammatory Response During Illness in Children With Respiratory Failure
Conditions: Acute Respiratory Failure;   Acute Respiratory Infection;   Acute Respiratory Distress Syndrome
Intervention:
Outcome Measures: Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum within 48-hours of mechanical ventilation;   Blood oxygenation saturation and hemodynamic changes following non-bronchoscopic BAL;   Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 3-4;   Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion, bronchial secretion, and serum between days 5-7
17 Recruiting T Cell Effector and Regulatory Mechanisms in Asthma
Conditions: Asthma;   Allergies
Interventions: Biological: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage;   Procedure: PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Outcome Measures: Differences in airway physiology and airway constriction;   Differences in BAL inflammatory mediator release;   Differences in cellular analysis of BAL;   Differences in BAL inflammatory protein levels
18 Recruiting Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Levofloxacin 500mg
Outcome Measures: mortality;   Rate of additional antibiotherapy course
19 Recruiting Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Condition: Alpha 1 Antitrypsin Deficiency
Intervention: Drug: Alpha-1 Antitrypsin (human)
Outcome Measures: CHANGES IN CYTOKINE PROFILE IN BRONCHOALVEOLAR LAVAGE;   CHANGES IN SERUM INFLAMMATORY MARKERS;   EFFECT OF DOUBLE DOSE ZEMAIRA ON ELASTIN DEGRADATION;   EFFECT OF DOUBLE DOSE ZEMAIRA ON NEUTROPHIL APOPTOSIS AND MIGRATION;   CHANGES IN NEUTROPHILIC LUNG INFILTRATION;   NUMBER OF ADVERSE EVENTS REPORTED;   CHANGES IN METABOLIC AND COAGULATION PROFILES
20 Recruiting Ecological Effects of Decolonisation Strategies in Intensive Care
Conditions: ICU-ecology (Multidrug Resistant Bacteria);   ICU-acquired Bacteraemia
Interventions: Drug: Chlorhexidine 2% mouthwash (CHX-Oro);   Drug: Selective oropharyngeal decontamination (SOD);   Drug: Selective Digestive Decontamination (SDD)
Outcome Measures: ICU-Ecology;   Cross-transmission rates;   Respiratory tract colonization;   ward-level systemic antibiotic use;   colonization in relation to bacteraemia;   transmission capacities of different bacteria;   Patient survival;   bacteraemia with resistant bacteria

These studies may lead to new treatments and are adding insight into Upper Respiratory Tract Inflammation etiology and treatment.

A major focus of Upper Respiratory Tract Inflammation research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Upper Respiratory Tract Inflammation